Alzheimer’s Reading Room “Anti-amyloid therapeutic drugs represent a valid approach to treating Alzheimer’s disease, but their inability to accumulate in the brain has limited their usefulness,” says Greengard, who is head of the Laboratory of Molecular and Cellular Neuroscience. “The development of compounds that work like Gleevec, but have…
GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE).
Original Source of GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for…
Bristol-Myers Squibb Company (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated.
Original Source of Ipilimumab Receives FDA Priority Review…
H. Lundbeck A/S (Lundbeck) reports second quarter revenue of DKK 3,767 million. An increase of 7% compared to the second quarter results of 2009. Profit from operations was DKK 936 million, an increase of 30% compared to the same period last year.
Original Source of Lundbeck reports strongly increasing profits…
Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix(R) (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer.
Original Source of Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial
Pfizer Inc. (NYSE: PFE) has reported financial results for second-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth products and operations are reflected in the first two quarters of 2010, but not reflected in the first two quarters of 2009.
Original Source of Pfizer…
An international team of scientists has identified 95 genetic variants associated with high blood cholesterol and triglyceride levels which are major risk factors for coronary heart disease. The study, published in the journal Nature and funded in part by the EU, could lead to novel ways of preventing and treating…
29 – 30 September 2010, Frankfurt, Germany. In the current environment where minimising cost and delivering ROI are critical themes within the pharma industry, improving your clinical trial infrastructure can ensure that time is not wasted and you are maximising your investments.
Original Source of Clinical Trials 2010 – Frankfurt…
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy.
Original Source of Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company.
Original Source of Shire Proposes to Expand Specialist…